[go: up one dir, main page]

MX2009003569A - Metodo de administracion de farmacos para la proteina anabolica osea. - Google Patents

Metodo de administracion de farmacos para la proteina anabolica osea.

Info

Publication number
MX2009003569A
MX2009003569A MX2009003569A MX2009003569A MX2009003569A MX 2009003569 A MX2009003569 A MX 2009003569A MX 2009003569 A MX2009003569 A MX 2009003569A MX 2009003569 A MX2009003569 A MX 2009003569A MX 2009003569 A MX2009003569 A MX 2009003569A
Authority
MX
Mexico
Prior art keywords
pthrp
administration
pharmacos
osea
stable
Prior art date
Application number
MX2009003569A
Other languages
English (en)
Inventor
Michael J Dey
Nathalie Mondoly
Benedicte Rigaud
Bart Henderson
C Richard Lyttle
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009003569(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of MX2009003569A publication Critical patent/MX2009003569A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención proporciona una composición estable en almacenamiento que contiene un análogo de la proteína relacionada con la hormona paratiroidea (PTHrP) y métodos de utilización de un análogo de PTHrP y de las composiciones de PTHrP aquí descritos para tratar la osteoporosis, para aumentar la masa ósea o para aumentar la calidad del hueso. La composición es estable en almacenamiento, en forma estéril, y en general puede ser almacenada a temperatura ambiente durante al menos varias semanas para permitir una conveniente administración parenteral a pacientes humanos.
MX2009003569A 2006-10-03 2007-10-03 Metodo de administracion de farmacos para la proteina anabolica osea. MX2009003569A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
PCT/US2007/021216 WO2008063279A2 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (1)

Publication Number Publication Date
MX2009003569A true MX2009003569A (es) 2009-08-25

Family

ID=39430237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003569A MX2009003569A (es) 2006-10-03 2007-10-03 Metodo de administracion de farmacos para la proteina anabolica osea.

Country Status (28)

Country Link
US (1) US8148333B2 (es)
EP (2) EP2957278B1 (es)
JP (1) JP5375611B2 (es)
KR (4) KR101512377B1 (es)
CN (2) CN101578093B (es)
AU (1) AU2007322334B2 (es)
BR (2) BRPI0719821B8 (es)
CA (1) CA2664734C (es)
CY (1) CY1119198T1 (es)
DK (2) DK2073789T3 (es)
ES (2) ES2637283T3 (es)
FR (1) FR23C1024I2 (es)
HR (1) HRP20171217T1 (es)
IL (1) IL197926A (es)
LT (1) LT2957278T (es)
LU (1) LUC00309I2 (es)
MX (1) MX2009003569A (es)
NL (1) NL301235I2 (es)
NO (1) NO344885B1 (es)
NZ (1) NZ576682A (es)
PL (1) PL2957278T3 (es)
PT (2) PT2073789T (es)
RS (1) RS56164B1 (es)
RU (1) RU2506070C2 (es)
SG (1) SG175580A1 (es)
SI (1) SI2957278T1 (es)
UA (1) UA98776C2 (es)
WO (1) WO2008063279A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
RS56164B1 (sr) 2006-10-03 2017-11-30 Radius Health Inc Stabilna kompozicija koja sadrži pthrp i njene upotrebe
MX342898B (es) 2010-05-12 2016-10-18 Radius Health Inc * Regimen terapéutico de la sal de diclorhidrato del (r) -6-(2-(etil (4-2(etilamino) etil) bencil) amino)-4-metoxifenil)-5, 6,7,8-tetrahidronaftaleno-2-ol.
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
CA2833571A1 (en) 2011-04-22 2012-10-26 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
CN108195965B (zh) * 2011-06-07 2021-02-23 旭化成制药株式会社 含pth肽冷冻干燥制剂的检査方法及包含该含pth肽冷冻干燥制剂的医药品的制造方法
CA2857502C (en) 2011-11-30 2019-08-13 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
SI3122426T1 (sl) 2014-03-28 2023-04-28 Duke University Zdravljenje raka dojk z uporabo selektivnih modulatorjev estrogenskih receptorjev
EP3265115B1 (en) * 2015-03-03 2022-06-22 Radius Health, Inc. Abaloparatide combined with alendronate for reducing non-vertebral bone fractures
IL255189B2 (en) 2015-04-29 2024-04-01 Radius Pharmaceuticals Inc A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer
CN108025042A (zh) * 2015-07-06 2018-05-11 董正欣 PTHrP类似物的新型制剂
CN106479329A (zh) 2015-08-31 2017-03-08 罗门哈斯电子材料有限责任公司 与外涂布光致抗蚀剂一起使用的涂料组合物
EP3359241B1 (en) * 2015-10-09 2021-04-14 Radius Health, Inc. Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
ES2904891T3 (es) 2016-04-18 2022-04-06 Radius Health Inc Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma
CA3027563C (en) 2016-06-22 2024-07-02 Ellipses Pharma Ltd AR+ METHODS FOR BREAST CANCER TREATMENT
EP3548012A4 (en) * 2016-11-30 2020-07-22 Purdue Research Foundation BONE REGENERATION TARGETED ON A FRACTURE BY STIMULATION OF THE PARATHYROID HORMONE RECEPTOR
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
WO2019175173A1 (en) * 2018-03-12 2019-09-19 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of pthrp analogue
WO2019232280A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2020010216A1 (en) 2018-07-04 2020-01-09 Radius Pharmaceuticals, Inc. Polymorphic forms of rad 1901-2hcl
PH12021551950A1 (en) 2019-02-12 2022-05-23 Radius Pharmaceuticals Inc Processes and compounds
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU688283B2 (en) 1992-09-29 1998-03-12 Novartis Ag Pulmonary delivery of active fragments of parathyroid hormone
CN1070500C (zh) 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
ATE297754T1 (de) 1997-09-09 2005-07-15 Hoffmann La Roche Heilung von bruchverletzungen unter verwendung von pthrp analogen
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7799757B2 (en) * 2002-06-13 2010-09-21 Michael Chorev Analogs of parathyroid hormone and PTH-related protein as bone anabolic agents
EP1567178A4 (en) 2002-11-01 2009-07-15 Amgen Inc MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
RS56164B1 (sr) 2006-10-03 2017-11-30 Radius Health Inc Stabilna kompozicija koja sadrži pthrp i njene upotrebe
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog

Also Published As

Publication number Publication date
KR20090083350A (ko) 2009-08-03
CY1119198T1 (el) 2018-02-14
ES2739459T3 (es) 2020-01-31
BRPI0719821A2 (pt) 2013-05-07
BRPI0722428A2 (pt) 2013-11-26
IL197926A (en) 2014-08-31
WO2008063279A3 (en) 2009-06-25
NL301235I2 (nl) 2023-08-31
HRP20171217T1 (hr) 2017-10-20
PT2073789T (pt) 2019-07-31
UA98776C2 (ru) 2012-06-25
BRPI0719821B8 (pt) 2021-05-25
EP2073789A2 (en) 2009-07-01
US8148333B2 (en) 2012-04-03
KR20180117738A (ko) 2018-10-29
NO344885B1 (no) 2020-06-15
AU2007322334B2 (en) 2011-12-22
EP2073789B1 (en) 2019-05-22
NO20091545L (no) 2009-05-27
KR101512377B1 (ko) 2015-04-28
WO2008063279A2 (en) 2008-05-29
WO2008063279A9 (en) 2008-07-10
FR23C1024I2 (fr) 2024-06-14
JP2010505835A (ja) 2010-02-25
IL197926A0 (en) 2011-08-01
JP5375611B2 (ja) 2013-12-25
EP2957278A1 (en) 2015-12-23
LT2957278T (lt) 2017-09-11
PL2957278T3 (pl) 2017-10-31
SG175580A1 (en) 2011-11-28
CA2664734C (en) 2023-08-01
NZ576682A (en) 2012-08-31
EP2957278B1 (en) 2017-05-17
LUC00309I2 (es) 2025-09-22
KR20170067906A (ko) 2017-06-16
DK2957278T3 (en) 2017-07-31
RS56164B1 (sr) 2017-11-30
CA2664734A1 (en) 2008-05-29
ES2637283T3 (es) 2017-10-11
SI2957278T1 (sl) 2017-09-29
CN102274492A (zh) 2011-12-14
HK1214181A1 (en) 2016-07-22
EP2073789B8 (en) 2023-02-08
CN102274492B (zh) 2014-11-26
FR23C1024I1 (fr) 2023-07-21
BRPI0719821B1 (pt) 2020-04-14
RU2009116531A (ru) 2010-11-10
PT2957278T (pt) 2017-08-23
CN101578093A (zh) 2009-11-11
KR20150020289A (ko) 2015-02-25
US20100029556A1 (en) 2010-02-04
DK2073789T3 (da) 2019-08-05
RU2506070C2 (ru) 2014-02-10
AU2007322334A1 (en) 2008-05-29
CN101578093B (zh) 2011-09-14

Similar Documents

Publication Publication Date Title
MX2009003569A (es) Metodo de administracion de farmacos para la proteina anabolica osea.
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
SG162788A1 (en) Self-buffering protein formulations
EA201500431A1 (ru) Соединения боронатного эфира и его фармацевтические составы
NO20073749L (no) Applikator for innforing av et implantat
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
MY161991A (en) Proteasome inhibitors
PH12012502279A1 (en) Tube feed formulations and methods for using same
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
EA200701519A1 (ru) Живая аттенуированная ротавирусная вакцина для перорального введения
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
PH12013502215A1 (en) Beautiful-skin-promoting agent and use thereof
MX2009005984A (es) Formulaciones con alta concentracion de proteina que contiene manitol.
ATE396697T1 (de) Zuckerlacton enthaltende zusammensetzung zur haarbehandlung
UA96794C2 (ru) Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе
EP2392322A3 (en) Dosing regimes for trans-clomiphene
CL2012000097A1 (es) Compuestos derivados de 3-fenoximetilpirrolidina, inhibidores de la recaptacion de serotonina-norepinefrina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos del dolor, depresion, entre otros.
DE602004019528D1 (de) Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
PE20061051A1 (es) Composicion farmaceutica que comprende mirtazapina s
UA105266C2 (ru) Композиция и способ борьбы с заболеваниями растений
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
WO2017007777A3 (en) NOVEL FORMULATIONS OF PTHrP ANALOGUE
EA200701598A1 (ru) Способ и композиция для восстановления эпителиальных и других клеток и тканей
MX2010009961A (es) Composicion transmucosica mejorada y forma de dosificacion.

Legal Events

Date Code Title Description
FG Grant or registration